Patient characteristics in medical claims analysis
| Melanoma | Lung cancer | Autoimmune disease | No autoimmune disease | |
| Total patients | 1672 | 1847 | 284 | 3230 |
| Average age | 62.9 | 67.1 | 65.6 | 65.1 |
| %Female | 34.8 | 50.2 | 50.0 | 42.2 |
| %Nivolumab | 13.0 | 96.2 | 53.9 | 57.0 |
| %Pembrolizumab | 18.9 | 3.8 | 13.0 | 10.8 |
| %Ipilimumab | 68.1 | N/A | 33.1 | 32.2 |
| %Ipilimumab-nivolumab combo | 2.45 | N/A | 2.5 | 1.3 |
| Median # ICI infusions, PD-1 Inhibitors | 2 | 4 | 3 | 3 |
| Median # ICI infusions, ipilimumab | 1 | N/A | 1 | 1 |